Nordisk
EU Regulator to Investigate Potential Link Between Ozempic and Rare Eye Condition NAION
Ozempic, NAION, European Medicines Agency, Novo Nordisk, semaglutide, eye disorder, diabetes drug, investigation
Novo Nordisk Invests $1.2 Billion in Rare Disease Production Facility in Denmark, Creating 400 New Jobs
Novo Nordisk, rare disease production, Denmark, new facility, job creation, pharmaceutical industry
Novo Nordisk Invests $1.2 Billion in New Danish Production Facility for Rare Disease Therapies
Novo Nordisk, rare disease drugs, Denmark, production facility, investment, hemophilia, pharmaceutical manufacturing
Zepbound Outperforms Wegovy in Weight Loss Trial, Offering Superior Efficacy
Zepbound, Wegovy, weight loss, tirzepatide, semaglutide, clinical trial, obesity medication, Eli Lilly, Novo Nordisk
Novavax Sells Czech Manufacturing Facility to Novo Nordisk for $200 Million
Novavax, Novo Nordisk, Czech manufacturing facility, cost-cutting, vaccine pipeline development
Novo Nordisk Invests $409M in New Quality Control Lab in Denmark
Novo Nordisk, quality control lab, Denmark, pharmaceutical investment, biotechnology
Lilly’s Zepbound Outshines Novo’s Wegovy in First Head-to-Head Weight Loss Study
Eli Lilly, Novo Nordisk, Zepbound, Wegovy, Weight Loss, Obesity Treatment, Head-to-Head Study, SURMOUNT-5
Pharmaceutical Giants Eli Lilly and Novo Nordisk Face Challenges Despite Strong Sales Growth
Eli Lilly, Novo Nordisk, Q3 2024 financial results, Obesity drugs, Weight loss therapies, Pharmaceutical industry challenges, Market competition, Supply pressures, Pricing issues
Novo Nordisk Terminates Development of Kidney Disease Drug Ocedurenone After Phase 3 Failure
Novo Nordisk, ocedurenone, kidney disease, hypertension, Phase 3 trial, CLARION-CKD, drug development failure
Novo Nordisk and Ascendis Pharma Collaborate on Groundbreaking Once-Monthly GLP-1 Treatment for Obesity and Type 2 Diabetes
Novo Nordisk, Ascendis Pharma, GLP-1 receptor agonist, once-monthly treatment, obesity, type 2 diabetes, metabolic diseases, cardiovascular therapies, TransCon technology.